featured
Subcutaneous vs Intravenous Nivolumab for Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Ann. Oncol 2024 Sep 15;[EPub Ahead of Print], L Albiges, MT Bourlon, M Chacón, HJ Cutuli, YAL Chuken, B Żurawski, JM Mota, I Magri, M Burotto, M Luz, J de Menezes, EPY Ruiz, S Fu, M Richardet, BP Valderrama, M Maruzzo, S Bracarda, M Breckenridge, HE Vezina, D Rathod, Z Yu, Y Zhao, M Dixon, D Perumal, S GeorgeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.